Infectious disease
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 5, 2020.
“We are genuinely honored at the opportunity to protect our military personnel and their families who have devoted themselves to the needs of U.S. citizens and others worldwide,” said Stanley C. Erck, president and chief executive officer of Novavax.
Inovio’s development issues for its vaccine candidate have become mired in a conflict with the contract manufacturing organization it has worked with on previous projects.
UK-based AstraZeneca and the University of Oxford have partnered on the global development and distribution of Oxford’s COVID-19 vaccine, AZD1222.
Questions continue to arise around a small company called Surgisphere and the data it collected that was used to form the results in two large COVID-19 studies, including one major study involving the use of the antimalarial drug hydroxychloroquine. Investigations are likely imminent as concerns over the data increase.
The fund, called the Emergency Support Instrument, would be used to increase vaccine manufacturing capacity in Europe.
The $7.4 billion raised would fund Gavi’s immunization programs between 2021 and 2025, which would help immunize 300 million children and potentially save 7 to 8 million lives.
Instead of detecting the virus, this device can help determine who might be at risk for intubation and mechanical ventilation.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 4, 2020.
Less than one month after the White House zeroed in on 14 vaccine candidates for COVID-19, the administration has narrowed that list even more to five potential treatments for the prevention of the novel coronavirus.
PRESS RELEASES